Changes in Aβ biomarkers and associations with APOE genotype in 2 longitudinal cohorts
- PMID: 26004017
- PMCID: PMC5084914
- DOI: 10.1016/j.neurobiolaging.2015.04.001
Changes in Aβ biomarkers and associations with APOE genotype in 2 longitudinal cohorts
Abstract
Apolipoprotein E (APOE) genotype influences onset age of Alzheimer's disease but effects on disease progression are less clear. We investigated amyloid-β (Aβ) levels and change in relationship to APOE genotype, using 2 different measures of Aβ in 2 different longitudinal cohorts. Aβ accumulation was measured using positron emission tomography (PET) imaging and (11)C-Pittsburgh compound-B (PiB) in 113 Baltimore Longitudinal Study of Aging participants (mean age 77.3 years; 107 normal, 6 cognitively impaired) and cerebral spinal fluid (CSF) Aβ1-42 assays in 207 BIOCARD study participants (mean age 62 years; 195 normal, 12 cognitively impaired). Participants in both cohorts had up to 7 serial assessments (mean 2.3-2.4). PET-PiB retention increased and CSF Aβ1-42 declined longitudinally. APOE ε4 was significantly associated with higher PET-PiB retention and lower CSF Aβ1-42, independent of age and sex, but APOE genotype did not significantly affect Aβ change over time. APOE ε4 carriers may be further along in the disease process, consistent with earlier brain Aβ deposition and providing a biological basis for APOE genotype effects on onset age of Alzheimer's disease.
Keywords: Apolipoprotein E genotype; Biomarkers; CSF Aβ(1-42); Longitudinal; PET amyloid imaging.
Copyright © 2015 Elsevier Inc. All rights reserved.
Conflict of interest statement
The terms of this arrangement are being managed by the Johns Hopkins University in accordance with its conflict of interest policies.
Figures



Similar articles
-
Association of plasma and cortical amyloid beta is modulated by APOE ε4 status.Alzheimers Dement. 2014 Jan;10(1):e9-e18. doi: 10.1016/j.jalz.2013.01.007. Epub 2013 Mar 26. Alzheimers Dement. 2014. PMID: 23541187 Free PMC article.
-
Proximity to Parental Symptom Onset and Amyloid-β Burden in Sporadic Alzheimer Disease.JAMA Neurol. 2018 May 1;75(5):608-619. doi: 10.1001/jamaneurol.2017.5135. JAMA Neurol. 2018. PMID: 29482212 Free PMC article.
-
Influence of apolipoprotein-E genotype on brain amyloid load and longitudinal trajectories.Neurobiol Aging. 2020 Oct;94:111-120. doi: 10.1016/j.neurobiolaging.2020.05.012. Epub 2020 May 31. Neurobiol Aging. 2020. PMID: 32603776 Free PMC article.
-
Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.JAMA Psychiatry. 2014 Oct;71(10):1183-91. doi: 10.1001/jamapsychiatry.2014.1060. JAMA Psychiatry. 2014. PMID: 25162367
-
APOE Effect on Amyloid-β PET Spatial Distribution, Deposition Rate, and Cut-Points.J Alzheimers Dis. 2019;69(3):783-793. doi: 10.3233/JAD-181282. J Alzheimers Dis. 2019. PMID: 31127775 Free PMC article.
Cited by
-
Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change.JAMA Neurol. 2016 Jun 1;73(6):698-705. doi: 10.1001/jamaneurol.2016.0194. JAMA Neurol. 2016. PMID: 27064267 Free PMC article.
-
Personality and Alzheimer's disease: An integrative review.Personal Disord. 2019 Jan;10(1):4-12. doi: 10.1037/per0000268. Personal Disord. 2019. PMID: 30604979 Free PMC article. Review.
-
Longitudinal Amyloid-β PET in Atypical Alzheimer's Disease and Frontotemporal Lobar Degeneration.J Alzheimers Dis. 2020;74(1):377-389. doi: 10.3233/JAD-190699. J Alzheimers Dis. 2020. PMID: 32039841 Free PMC article.
-
Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer's disease.Acta Neuropathol. 2020 Oct;140(4):463-476. doi: 10.1007/s00401-020-02175-1. Epub 2020 Aug 9. Acta Neuropathol. 2020. PMID: 32772265 Free PMC article.
-
Population pharmacokinetic-pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease.CPT Pharmacometrics Syst Pharmacol. 2022 Dec;11(12):1578-1591. doi: 10.1002/psp4.12862. Epub 2022 Sep 27. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 36165093 Free PMC article.
References
-
- Khachaturian AS, Corcoran CD, Mayer LS, Zandi PP, Breitner JC Cache County Study I. Apolipoprotein E epsilon4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: The Cache County Study. Arch Gen Psychiatry. 2004 May;61(5):518–524. - PubMed
-
- Slooter AJ, Houwing-Duistermaat JJ, van Harskamp F, et al. Apolipoprotein E genotype and progression of Alzheimer's disease: the Rotterdam Study. J Neurol. 1999 Apr;246(4):304–308. - PubMed
-
- Bracco L, Piccini C, Baccini M, et al. Pattern and progression of cognitive decline in Alzheimer's disease: role of premorbid intelligence and ApoE genotype. Dement Geriatr Cogn Disord. 2007;24(6):483–491. - PubMed
-
- Martins CA, Oulhaj A, de Jager CA, Williams JH. APOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model. Neurology. 2005 Dec 27;65(12):1888–1893. - PubMed
-
- Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiology of aging. 2010 Aug;31(8):1275–1283. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous